Table 1. Demographics and characteristics of patients completing phase 3 cardiac rehabilitation.

Total number of patients	33
Mean age, years	69.9 ± 1.7
Female, n (%)	19 (58%)
Atrial fibrillation type, n (%) Paroxysmal Persistent Permanent	15 (45.5%) 16 (48.5%) 2 (6%)
Hypertension, n (%)	20 (60%)
Hypercholesterolaemia, n (%)	14 (42%)
Heart failure, n (%)	5 (15%)
Ischaemic heart disease, n (%)	5 (15%)
Diabetes, n (%)	5 (15%)
Obstructive sleep apnoea, n (%)	4 (12%)
Previous ablation for AF, n (%) Catheter ablation Surgical ablation	5 (15%) 4 (12%) 1 (3%)
Medications, n (%) Beta blocker Digoxin ACE inhibitor Angiotensin-receptor antagonist Anti-arrhythmic therapy Warfarin Direct oral anticoagulant Not anticoagulated	27 (82%) 2 (6%) 10 (30%) 5 (15%) 14 (42%) 6 (18%) 26 (79%) 1 (3%)
Transthoracic echocardiogram measurements
Left ventricular systolic function, n(%) Preserved Mild LVSD Moderate LVSD Severe LVSD	28 (85%) 2 (6%) 2 (6%) 1 (3%)
Valvular disease, n (%) Moderate MR Moderate AS	4 (12%) 1 (3%)
Left atrial size, cm	5.1 ± 1.8

Key: ACE = angiotensin-converting enzyme; AF = atrial fibrillation; AS = aortic stenosis; LVSD = left ventricular systolic dysfunction; MR = mitral regurgitation